ArticleNature communications2022

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.

Raphael Reinbold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.